Trial Profile
A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Encorafenib (Primary) ; Vemurafenib
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms COLUMBUS
- Sponsors Array BioPharma; Novartis; Pfizer
- 08 Feb 2024 Planned End Date changed from 30 Nov 2023 to 31 Mar 2024.
- 24 Oct 2023 Results (n=577) from from the 7-year analysis of COLUMBUS part 1 presented at the 48th European Society for Medical Oncology Congress
- 28 Jul 2023 Results (n=280) published in the Journal of Clinical Oncology